
Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
WolverHeme Happy Hour
00:00
The Role of Rituxin in Leukemia Treatment
The GRAL-05 study looked at two different randomizations, one of which was hyper-fractionated cytoxin during induction and late intensification. And they saw a longer event-free survival with Rituximab compared to the control group. But again, probably underpowered. So we see this study, we see that outcomes are improved with addition to Rituxin.
Transcript
Play full episode